These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26263487)

  • 1. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
    Gallay PA; Bobardt MD; Chatterji U; Trepanier DJ; Ure D; Ordonez C; Foster R
    PLoS One; 2015; 10(8):e0134707. PubMed ID: 26263487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.
    Gallay PA; Chatterji U; Bobardt MD; Long Z; Zhang S; Su Z
    PLoS One; 2016; 11(4):e0152036. PubMed ID: 27104614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
    Hopkins S; Bobardt M; Chatterji U; Garcia-Rivera JA; Lim P; Gallay PA
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3888-97. PubMed ID: 22585215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
    Gallay P; Ure D; Bobardt M; Chatterji U; Ou J; Trepanier D; Foster R
    PLoS One; 2019; 14(6):e0217433. PubMed ID: 31181107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.
    Chatterji U; Bobardt M; Schaffer L; Wood M; Gallay PA
    PLoS One; 2016; 11(7):e0159511. PubMed ID: 27442520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.
    Chatterji U; Bobardt M; Tai A; Wood M; Gallay PA
    Antimicrob Agents Chemother; 2015 May; 59(5):2496-507. PubMed ID: 25666154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    Bobardt M; Ramirez CM; Baum MM; Ure D; Foster R; Gallay PA
    PLoS One; 2021; 16(5):e0251934. PubMed ID: 34014993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.
    Chatterji U; Lim P; Bobardt MD; Wieland S; Cordek DG; Vuagniaux G; Chisari F; Cameron CE; Targett-Adams P; Parkinson T; Gallay PA
    J Hepatol; 2010 Jul; 53(1):50-6. PubMed ID: 20451281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophilin inhibitors for the treatment of HCV infection.
    Fischer G; Gallay P; Hopkins S
    Curr Opin Investig Drugs; 2010 Aug; 11(8):911-8. PubMed ID: 20721833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
    Fu J; Tjandra M; Becker C; Bednarczyk D; Capparelli M; Elling R; Hanna I; Fujimoto R; Furegati M; Karur S; Kasprzyk T; Knapp M; Leung K; Li X; Lu P; Mergo W; Miault C; Ng S; Parker D; Peng Y; Roggo S; Rivkin A; Simmons RL; Wang M; Wiedmann B; Weiss AH; Xiao L; Xie L; Xu W; Yifru A; Yang S; Zhou B; Sweeney ZK
    J Med Chem; 2014 Oct; 57(20):8503-16. PubMed ID: 25310383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophilin inhibitors.
    Gallay PA
    Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.
    Zhang J; Mulvenon A; Makarov E; Wagoner J; Knibbe J; Kim JO; Osna N; Bronich TK; Poluektova LY
    Biomaterials; 2013 May; 34(15):3846-57. PubMed ID: 23403120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.
    Nag A; Robotham JM; Tang H
    J Virol; 2012 Dec; 86(23):12616-24. PubMed ID: 22973029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.